← Back to all trials
Active Not Recruiting
NCT07924865
Effects Of Topical Clobetasol Versus Coconut Oil Cream In The Treatment Of Oral Lichen Planus
Conditions: Comparative Effectiveness, Comparative Effectiveness Study, Oral Lichen Planus
Sex: All
Ages: 18 Years – 60 Years
Healthy volunteers: No
Phase: NA
Enrollment: 116
Sponsor: Imaduddin Wasif
Location: Abbasi Shaheed Hospital Karachi Karachi Sindh
Summary
The goal of this clinical trial is to learn if coconut oil cream works to treat oral lichen planus (OLP) in adults. It will also compare its effects and safety with clobetasol, a commonly used treatment for OLP. The main questions it aims to answer are:
* Does coconut oil cream reduce the size of oral lichen planus lesions?
* Does it reduce burning or pain in the mouth?
* What medical problems or side effects do participants have during treatment?
Researchers will compare coconut oil cream with clobetasol ointment to see how well each treatment works for oral lichen planus.
Participants will:
* Be randomly assigned to receive coconut oil cream or clobetasol ointment.
* Apply their assigned treatment twice a day for 14 weeks.
* Visit the clinic regularly for checkups and assessment of their oral lesions.
* Have the size of their lesions measured and their burning sensation recorded during follow-up visits.
* Be monitored for possible side effects such as mouth irritation, allergic reactions, oral fungal infection, or worsening of lesions.
* If a participant receiving coconut cream does not improve or becomes worse within 2-4 weeks, they will be offered clobetasol as rescue treatment.
Eligibility Criteria
Inclusion Criteria:
* Age 18 to 60 years
* Either gender
* Clinically confirmed cases of Oral Lichen Planus (OLP)
Exclusion Criteria:
* Patients with other potentially malignant disorders and under treatment for the same
* Pregnant patients
* Lactating mothers
* Patients undergoing/who underwent some form of OLP treatment within 3 months Those with known allergy to any of the preparations (coconut oil cream components or clobetasol) Patients with uncontrolled systemic diseases including diabetes mellitus, hypertension, autoimmune disorders, hepatic or renal impairment
Source: ClinicalTrials.gov (NCT07924865). StuddyBuddy aggregates publicly available trial information.